Shoulder Pain

- National clinical review and contract offers an easier path to care for millions of Veterans - CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- SPR announced today that the SPRINT PNS System is now available on the Department of Veteran’s Affairs (VA) Surgical Implants-Next Generation (SING) contract via a distribution agreement with ERA Health, LLC dba Veteran’s Health Medical Supply (VHMS). The addition of SPRINT PNS to this contract will provide VA healthcare providers greater access and ease of purchase via VHMS federal contracts. The SPRINT PNS System is also currently available on the Distribution and Pricing Agreement (DAPA) and ECAT federal contracts. This new agreement with VHMS will offer physicians working in Veterans Affairs easier access to the SPRINT System and incorporate the support of VHMS staff and their longstanding relationships with purchasing staff at these facilities. The increased visibility within the VA network is a significant benefit to SPR as the SPRINT PNS System continues to see rapid adoption in the marketplace. The Veteran’s Health Administration has a significant reach throughout the U.S. with 170 VA Medical Centers and 1,193 outpatient sites of care that can deliver support to over 9.1 million Veterans enrolled in the VA health care program. “We are proud to continually expand access opportunities for those that can benefit from our SPRINT PNS treatment, and it is particularly important to provide our veterans who served our country appropriate solutions with the potential for long-term relief to help address their pain,” said Maria Bennett, President, CEO, and Founder of SPR. “Products included under this SING contract go through a comprehensive national clinical review which can help streamline the local product committee process in providing access to patients that are in need of care.” About the SPRINT PNS System The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™ More information can be found at www.SPRPainRelief.com. SPR Contacts:Michelle McDonaldVice President – MarketingMichelle.McDonald@SPRPainRelief.com844.378.9108 Dave FolkensPublic Relations Dave.Folkens@SPRPainRelief.com612.978.6547

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter study that demonstrated significant and sustained pain relief more than four years after treatment with 60-day minimally invasive peripheral nerve stimulation (PNS) for chronic low back pain. To understand the long-term impact of treatment with SPRINT PNS, surveys were sent to participants from a prior prospective multicenter study who reported clinically meaningful reductions in pain, disability, or pain interference. The current publication, “Four-year follow-up from a prospective, multicenter study of percutaneous 60-day peripheral nerve stimulation for chronic low back pain” appears in Pain and Therapy and the findings indicate that, “Percutaneous 60-day PNS can provide durable outcomes that are often sustained for multiple years by patients with chronic axial low back pain who subsequently avoid the need for more invasive treatment interventions.” Key Results A majority of long-term respondents (70 percent,16/23) reported clinically substantial (greater than or equal to 50 percent) pain relief and/or clinically meaningful improvements in disability (greater than or equal to 10-point improvement on the Oswestry Disability Index) four or more years after 60-day SPRINT PNS.An average of four or more years after SPRINT PNS, 70 percent (16/23) of respondents were able to avoid progression to more costly, invasive, or destructive low back pain interventions.Safety outcomes were not specifically analyzed in the long-term follow-up survey. Lead author Dr. Christopher Gilmore, MD, of Carolinas Pain Institute and SPR consultant noted, “The sustained pain relief seen in these patients is very impressive given the time since treatment and the strain that real-world physical activity can place on low back pain patients. To see four or more years of continued performance is outstanding; the fact that a majority of respondents have avoided the need for costly invasive implants or destructive surgical intervention suggests this device has had a major impact on their lives.” “We continue to be encouraged by the clinical outcomes we’re seeing in real-world settings for patients in managing their pain,” said Maria Bennett, President, CEO, and Founder of SPR. “Long-lasting pain relief of more than four years that has been experienced by some of these patients is life-changing, allowing them to reclaim their lives.” About the SPRINT PNS System The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™ More information can be found at www.SPRPainRelief.com. SPR Contacts:Michelle McDonaldVice President – MarketingMichelle.McDonald@SPRPainRelief.com844.378.9108 Dave FolkensPublic Relations Dave.Folkens@SPRPainRelief.com612.978.6547

CLEVELAND, Dec. 13, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics has been named to the Crain’s Cleveland Business Fast 50, placing first on the list of rapidly growing, privately held companies ranked by revenue growth over the last five years. In the past five years, the SPRINT® Peripheral Nerve Stimulation (PNS) System has seen tremendous growth in use by physicians within the marketplace to treat pain throughout the body via a 60-day treatment that has been proven in clinical studies to provide significant and sustained relief. Maria Bennett, President, CEO, and Founder of SPR said, “We are honored to be included in this impressive list of companies that are making significant strides in advancing the business community in our region. The level of success and growth we’ve had in the past five years wouldn’t be possible without the extraordinary work and commitment of our team, and I want to thank them for everything they do for our patients.” The company recently announced positive primary endpoint data from its largest randomized controlled trial to-date utilizing SPRINT PNS in the treatment of chronic low back pain. The RESET® Trial evaluated pain and improvement in function and quality of life in SPRINT PNS subjects compared to those receiving Standard Interventional Treatment three months after start of treatment. SPR continues to research and study the effectiveness of PNS treatment to provide patients with a clinically proven, non-opioid, and non-surgical option for patients to address their pain. About the SPRINT PNS System The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options. The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only. For additional information regarding safety and efficacy, visit: SPR Safety Information. About SPR Therapeutics, Inc.SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. More information can be found at www.SPRTherapeutics.com. SPR Contacts:Michelle McDonaldVice President – Marketingmmcdonald@sprtherapeutics.com 844.378.9108 Dave FolkensPublic Relations dfolkens@sprtherapeutics.com 612.978.6547